Summary
- Profile Type
- Research & Development Request
- POD Reference
- RDRNL20260811015
- Term of Validity
- 11 August 2026 - 11 August 2027
- Company's Country
- Netherlands
- Type of partnership
- Research and development cooperation agreement
- Targeted Countries
- All countries
General information
- Short Summary
- A Dutch university department specialising in family medicine and medication safety research is seeking to join a Horizon Europe consortium (HORIZON-HLTH-2027-01-CARE-02) developing personalised approaches to reduce adverse drug reaction risks from multiple medications. It wishes to join as a project partner or work package leader, contributing expertise in polypharmacy, deprescribing, pragmatic trials and real-world data.
- Full Description
-
This expression of interest comes from a university department of family medicine in the Netherlands, active in medication safety, implementation science and primary care research. The organisation is seeking to join an existing or forming consortium under the Horizon Europe topic HORIZON-HLTH-2027-01-CARE-02: Personalised Approaches to Reduce Risks from Adverse Drug Reactions due to Administration of Multiple Medications, as a project partner or, depending on the consortium's needs, as a work package leader.
The project it wishes to contribute to addresses adverse drug reactions (ADRs) linked to taking multiple medications at once (polypharmacy), a growing patient-safety concern, especially among older adults and people with complex medication regimens. The call seeks more personalised, evidence- and biomarker-guided prescribing decisions, safer deprescribing, and better integration of clinical decision-support tools into everyday primary care.
The organisation can contribute expertise in medication optimisation and safety in primary care, pragmatic clinical trials, implementation science, and the use of real-world data, including electronic health records, to evaluate and scale up personalised prescribing and deprescribing interventions. It can help generate real-world evidence on the clinical utility and cost-effectiveness of biomarker-guided prescribing, support integration of clinical decision-support systems into primary care workflows, and help address behavioural and organisational barriers to adopting personalised medicine among healthcare professionals. - Sustainable Development Goals
- Goal 3: Good Health and Well-being
Partner Sought
- Expected Role of a Partner
-
As a partner within the consortium, the department would take responsibility for work on medication optimisation and safety in primary care, particularly polypharmacy, deprescribing, psychotropic medication, and reducing medication-related harm through patient-centred interventions. It is prepared to lead or substantially contribute to a work package covering pragmatic clinical trials, implementation science and mixed-methods research, including the design, evaluation and scale-up of complex interventions, process evaluations, and co-design with patients and healthcare professionals.
Specific tasks it could perform include: generating real-world evidence on the clinical utility and cost-effectiveness of biomarker-guided prescribing; evaluating the integration of clinical decision-support systems into primary care workflows using electronic health record data; and identifying and addressing implementation, behavioural and organisational barriers to the adoption of personalised medicine by healthcare professionals. Its experience in pragmatic trials, process evaluation and stakeholder co-design is expected to support translating project results into sustainable clinical practice.
It would also bring supporting infrastructure and data assets, including longitudinal primary care electronic health record data, prescribing data, registry data and patient-reported outcomes; expertise with implementation frameworks such as the Theoretical Domains Framework; access to a Dutch academic primary care research network; and the possibility of piloting and evaluating interventions in a routine primary care setting.
Relevant track record includes a pragmatic cluster randomised trial on collaborative primary care for antidepressant deprescribing (GPS-AD, 2025–2029, funded by the KCE Trials Program, Belgium, €1.14M), and an earlier pragmatic cluster randomised trial on blended care to discontinue long-term benzodiazepine receptor agonist use (Big Bird trial, 2018–2022, funded by the KCE Trials Program, Belgium, €2.2M), plus registry-based studies and qualitative co-creation research on digital health tools and implementation guidelines.
The exact scope of tasks and deliverables would need to be agreed jointly with the coordinating consortium, depending on the work package structure and overall project needs. - Type and Size of Partner
- University
- Type of partnership
- Research and development cooperation agreement
Call details
- Framework program
- Health
- Call title and identifier
-
HORIZON-HLTH-2027-01-CARE-02
- Submission and evaluation scheme
-
Single stage
- Anticipated project budget
-
8-10M
- Coordinator required
-
No
- Deadline for EoI
- Deadline of the call
- Health
Dissemination
- Market keywords
- 05001007 - Other diagnostic
- Sector Groups Involved
- Health
- Targeted countries
- All countries